Advanced

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries.

Chen, Tianhui; Fallah, Mahdi; Brenner, Hermann; Jansen, Lina; Mai, Elias K; Castro, Felipe A; Katalinic, Alexander; Emrich, Katharina; Holleczek, Bernd and Geiss, Karla, et al. (2016) In Scientific Reports 6.
Abstract
We aimed at investigating the distribution and risk of second primary cancers (SPCs) in multiple myeloma (MM) survivors in Germany and Sweden to provide etiological understanding of SPCs and insight into their incidence rates and recording practices. MM patients diagnosed in 1997-2010 at age ≥15 years were selected from the Swedish (nationwide) and 12 German cancer registries. Standardized incidence ratios (SIRs) were used to assess risk of a specific SPC compared to risk of the same first cancer in the corresponding background population. Among 18,735 survivors of first MM in Germany and 7,560 in Sweden, overall 752 and 349 SPCs were recorded, respectively. Significantly elevated SIRs of specific SPCs were observed for acute myeloid... (More)
We aimed at investigating the distribution and risk of second primary cancers (SPCs) in multiple myeloma (MM) survivors in Germany and Sweden to provide etiological understanding of SPCs and insight into their incidence rates and recording practices. MM patients diagnosed in 1997-2010 at age ≥15 years were selected from the Swedish (nationwide) and 12 German cancer registries. Standardized incidence ratios (SIRs) were used to assess risk of a specific SPC compared to risk of the same first cancer in the corresponding background population. Among 18,735 survivors of first MM in Germany and 7,560 in Sweden, overall 752 and 349 SPCs were recorded, respectively. Significantly elevated SIRs of specific SPCs were observed for acute myeloid leukemia (AML; SIR = 4.9) in Germany and for kidney cancer (2.3), AML (2.3) and nervous system cancer (1.9) in Sweden. Elevated risk for AML was more pronounced in the earlier diagnosis period compared to the later, i.e., 9.7 (4.2-19) for 1997-2003 period versus 3.5 (1.5-6.9) for 2004-2010 in Germany; 3.8 (1.4-8.3) for 1997-2003 versus 2.2 (0.3-7.8) for 2004-2010 in Sweden. We found elevated risk for AML for overall, early diagnosis periods and longer follow-up times in both populations, suggesting possible side effects of treatment for MM patients. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scientific Reports
volume
6
publisher
Nature Publishing Group
external identifiers
  • pmid:26908235
  • scopus:84959221052
  • wos:000370748500001
ISSN
2045-2322
DOI
10.1038/srep22084
language
English
LU publication?
yes
id
58592cdf-92b5-421d-aca9-1b101a5017a7 (old id 8821845)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26908235?dopt=Abstract
date added to LUP
2016-03-02 15:18:04
date last changed
2017-02-05 03:49:00
@article{58592cdf-92b5-421d-aca9-1b101a5017a7,
  abstract     = {We aimed at investigating the distribution and risk of second primary cancers (SPCs) in multiple myeloma (MM) survivors in Germany and Sweden to provide etiological understanding of SPCs and insight into their incidence rates and recording practices. MM patients diagnosed in 1997-2010 at age ≥15 years were selected from the Swedish (nationwide) and 12 German cancer registries. Standardized incidence ratios (SIRs) were used to assess risk of a specific SPC compared to risk of the same first cancer in the corresponding background population. Among 18,735 survivors of first MM in Germany and 7,560 in Sweden, overall 752 and 349 SPCs were recorded, respectively. Significantly elevated SIRs of specific SPCs were observed for acute myeloid leukemia (AML; SIR = 4.9) in Germany and for kidney cancer (2.3), AML (2.3) and nervous system cancer (1.9) in Sweden. Elevated risk for AML was more pronounced in the earlier diagnosis period compared to the later, i.e., 9.7 (4.2-19) for 1997-2003 period versus 3.5 (1.5-6.9) for 2004-2010 in Germany; 3.8 (1.4-8.3) for 1997-2003 versus 2.2 (0.3-7.8) for 2004-2010 in Sweden. We found elevated risk for AML for overall, early diagnosis periods and longer follow-up times in both populations, suggesting possible side effects of treatment for MM patients.},
  articleno    = {22084},
  author       = {Chen, Tianhui and Fallah, Mahdi and Brenner, Hermann and Jansen, Lina and Mai, Elias K and Castro, Felipe A and Katalinic, Alexander and Emrich, Katharina and Holleczek, Bernd and Geiss, Karla and Eberle, Andrea and Sundquist, Kristina and Hemminki, Kari},
  issn         = {2045-2322},
  language     = {eng},
  publisher    = {Nature Publishing Group},
  series       = {Scientific Reports},
  title        = {Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries.},
  url          = {http://dx.doi.org/10.1038/srep22084},
  volume       = {6},
  year         = {2016},
}